Literature DB >> 26082490

Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.

Jingfang Zhang1, Erik A Ranheim2, Juan Du1, Yangang Liu1, Jinyong Wang1, Guangyao Kong1, Jing Zhang3.   

Abstract

Activating Ras signaling is a major driver in juvenile and the myeloproliferative variant of chronic myelomonocytic leukemia (JMML/MP-CMML). Numerous studies suggest that GM-CSF signaling plays a central role in establishing and maintaining JMML/MP-CMML phenotypes in human and mouse. However, it remains elusive how GM-CSF signaling impacts on JMML/MP-CMML initiation and progression. Here, we investigate this issue in a well characterized MP-CMML model induced by endogenous Nras(G12D/+) mutation. In this model, Nras(G12D/+) hematopoietic stem cells (HSCs) are required to initiate and maintain CMML phenotypes and serve as CMML-initiating cells. We show that the common β chain of the GM-CSF receptor (βc) is dispensable for Nras(G12D/+) HSC function; loss of βc does not affect the expansion, increased self-renewal, or myeloid differentiation bias in Nras(G12D/+) HSCs. Therefore, βc(-/-) does not abrogate CMML in Nras(G12D/+) mice. However, βc deficiency indeed significantly reduces Nras(G12D/+)-induced splenomegaly and spontaneous colony formation and prolongs the survival of CMML-bearing mice, suggesting that GM-CSF signaling plays an important role in promoting CMML progression. Together, our results suggest that inhibiting GM-CSF signaling in JMML/MP-CMML patients might alleviate disease symptoms but would not eradicate the disease.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  animal model; beta common receptor; cancer stem cells; cell signaling; chronic myelomonocytic leukemia; oncogene; oncogenic Nras; transgenic mice

Mesh:

Substances:

Year:  2015        PMID: 26082490      PMCID: PMC4521033          DOI: 10.1074/jbc.M115.653154

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Inducible gene targeting in mice.

Authors:  R Kühn; F Schwenk; M Aguet; K Rajewsky
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

2.  Nf1 and Gmcsf interact in myeloid leukemogenesis.

Authors:  R A Birnbaum; A O'Marcaigh; Z Wardak; Y Y Zhang; G Dranoff; T Jacks; D W Clapp; K M Shannon
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

3.  Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors.

Authors:  P D Emanuel; L J Bates; R P Castleberry; R J Gualtieri; K S Zuckerman
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113

4.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

Review 5.  Chronic myelomonocytic leukemia: myeloproliferative variant.

Authors:  Francesco Onida; Miloslav Beran
Journal:  Curr Hematol Rep       Date:  2004-05

6.  Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal.

Authors:  R Nishinakamura; N Nakayama; Y Hirabayashi; T Inoue; D Aud; T McNeil; S Azuma; S Yoshida; Y Toyoda; K Arai
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

7.  Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Authors:  Jinyong Wang; Guangyao Kong; Yangang Liu; Juan Du; Yuan-I Chang; Sin Ruow Tey; Xinmin Zhang; Erik A Ranheim; Marc K Saba-El-Leil; Sylvain Meloche; Alisa Damnernsawad; Jingfang Zhang; Jing Zhang
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

8.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

9.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

10.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Authors:  Doan T Le; Namie Kong; Yuan Zhu; Jennifer O Lauchle; Abigail Aiyigari; Benjamin S Braun; Endi Wang; Scott C Kogan; Michelle M Le Beau; Luis Parada; Kevin M Shannon
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  5 in total

1.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

Review 2.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

Review 3.  Mouse Models of CMML.

Authors:  Ekaterina Belotserkovskaya; Oleg Demidov
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

4.  Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.

Authors:  Anthony M Hunter; Hannah Newman; Amy E Dezern; David P Steensma; Sandrine Niyongere; Gail J Roboz; Qianxing Mo; Onyee Chan; Aaron Gerds; David A Sallman; William Dominguez-Viqueira; Christopher Letson; Maria E Balasis; Markus Ball; Traci Kruer; Hailing Zhang; Jeffrey E Lancet; Alan F List; Mikkael A Sekeres; Rami S Komrokji; Eric Padron
Journal:  Clin Cancer Res       Date:  2021-07-12       Impact factor: 12.531

Review 5.  Sex chromosome loss and the pseudoautosomal region genes in hematological malignancies.

Authors:  Stephanie Weng; Samuel A Stoner; Dong-Er Zhang
Journal:  Oncotarget       Date:  2016-11-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.